Dr. Qu Zhican, Chairman of Nanolattix, Attends Dingxiangyuan BD Collaboration Salon and Delivers Keynote Speech
Release time:
2025-11-04
On October 31, 2025, the Insight 12th Anniversary · SAPA Special — BD Collaboration Salon, hosted by Dingxiangyuan, was held in Suzhou. Dr. Qu Zhican, Chairman of Nanolattix, was invited to attend and deliver a keynote speech. Together with representatives from pharmaceutical companies, biotech firms, investment institutions, and research academies, they focused on the latest trends and collaboration opportunities in global pharmaceutical transactions.
In his speech, Dr. Qu Zhican systematically introduced Nanolattix's anti-tumor drug pipeline, developed based on its self-established BioLattix technology platform. Key pipeline projects highlighted included the ADC drug T320, bispecific ADC drugs B836 and B830, and the RDC drug RT01. The presentation fully demonstrated Nanolattix's R&D capabilities and differentiated strategy in the biopharmaceutical field. Dr. Qu also engaged in in-depth discussions with investors and corporate representatives on collaboration pathways and development strategies.
The series of innovative drug pipelines built on Nanolattix's BioLattix platform have demonstrated promising preclinical potential and development prospects. We look forward to leveraging this salon as an opportunity to establish collaborations with more industry partners, jointly advancing the R&D and commercialization of innovative anti-tumor drugs to provide patients with better treatment options.
Tag:
recommend News
Share
